Inventiva announces its preliminary financial results for 2025

The biopharmaceutical company Inventiva has published its preliminary financial results for 2025. Cash and cash equivalents amount to €99.3 million, with short-term deposits totaling €131.6 million. Annual revenue is €4.5 million, down from €9.2 million in 2024.

Inventiva successfully completed a public offering in the United States, generating gross proceeds of $172.5 million. Net operating cash flow was -€104.6 million, primarily due to a pipeline prioritization strategy and lower revenues related to the agreement with Chia Tai Tianqing Pharmaceutical Group. The company anticipates its financial resources will support its operations until early 2027.